Gain Therapeutics (GANX) Share-based Compensation (2020 - 2026)
Gain Therapeutics (GANX) posted quarterly Share-based Compensation of $63970.0 for Q1 2026, down 84.88% year-over-year from $423145.0 in Q1 2025, and down 83.54% quarter-over-quarter from $388757.0 in Q4 2025.
Gain Therapeutics (GANX) Share-based Compensation (2020 - 2026) Analysis & Trends
Gain Therapeutics' Share-based Compensation history runs 7 years deep, the most recent figure standing at $63970.0 for Q1 2026.
- In Q1 2026, Share-based Compensation fell 84.88% year-over-year to $63970.0; the TTM figure through Mar 2026 stood at $63970.0 (down 97.65% YoY), while the FY2025 annual figure was $3.1 million, up 29.7% from the prior year.
- Share-based Compensation for Q1 2026 stood at $63970.0, down from $388757.0 in the prior quarter.
- The five-year high for Share-based Compensation was $3.5 million in Q3 2025, with the low at $63970.0 in Q1 2026.
- The 5-year median for Share-based Compensation is $459810.0 (2024), against an average of $714086.9.
- The sharpest annual moves came in 2025 and 2026: Share-based Compensation soared 879.01% in 2025, then slumped 84.88% in 2026.
- Gain Therapeutics' Share-based Compensation stood at $558692.0 in 2022, then dropped by 0.65% to $555059.0 in 2023, then retreated by 17.16% to $459810.0 in 2024, then declined by 15.45% to $388757.0 in 2025, then slumped by 83.54% to $63970.0 in 2026.
- Business Quant data shows GANX's Share-based Compensation at $63970.0 in Q1 2026, $388757.0 in Q4 2025, and $3.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.01 Bn | 132.16 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.79 Bn | 78.79 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.18 Bn | 55.04 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.55 Bn | 28.24 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.45 Bn | 10.06 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.19 Bn | 26.36 Bn | - | - |
| 10 | Gain Therapeutics | 87.26 Mn | 87.26 Mn | - | 566,049.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 566,049.00 |
| Jun 30, 2026 | 566,049.00 |
| Mar 31, 2026 | 63,970.00 |
| Mar 31, 2026 | 63,970.00 |
| Dec 31, 2025 | 388,757.00 |
| Dec 31, 2025 | 388,757.00 |
| Sep 30, 2025 | 3.50 Mn |
| Sep 30, 2025 | 3.50 Mn |
| Jun 30, 2025 | 530,499.00 |
| Jun 30, 2025 | 530,499.00 |
| Mar 31, 2025 | 423,145.00 |
| Mar 31, 2025 | 423,145.00 |
| Dec 31, 2024 | 459,810.00 |
| Dec 31, 2024 | 459,810.00 |
| Sep 30, 2024 | 357,505.00 |
| Sep 30, 2024 | 357,505.00 |
| Jun 30, 2024 | 1.48 Mn |
| Jun 30, 2024 | 1.48 Mn |
| Mar 31, 2024 | 145,473.00 |
| Mar 31, 2024 | 145,473.00 |